A double Schiff base iron complex and its preparation method and application

By developing a bischiff alkali iron complex and using 5-halogenated salicylic acid 1,3-propylenediamine derivative to react with Fe, the problems of low selectivity and toxic side effects of existing metal anti-cancer drugs have been solved, and efficient killing and low toxicity of tumor cells has been achieved, with good application prospects.

CN116730863BActive Publication Date: 2025-03-21GUANGXI NORMAL UNIV
2 Cites 0 Cited by

Patent Information

Application Number
CN202310716452.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-06-16
Publication Date
2025-03-21
Estimated Expiration
2043-06-16

AI Technical Summary

Technical Problem

Existing metal anti-cancer drugs such as cisplatin have low selectivity and serious toxic side effects, which leads to poor effectiveness in treating tumors, and the development of iron-based anti-cancer drugs is lacking and insufficient efficacy.

Method used

A bischiff base iron complex was developed, prepared by reacting 5-halogenated salicylic acid 1,3-propylenediamine derivative with Fe to adjust the anti-cancer effect of the complex.

Benefits of technology

The TwinSchiff alkaline iron complex showed good anti-cancer activity and selectivity in in vitro and in vivo experiments, especially on the Hep-G2 cell line, with the best anti-tumor effect, with lower IC50 values ​​than cisplatin, and no obvious toxic side effects in in vivo treatment and high safety.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present invention relates to the field of anti-tumor drugs, and in particular to a bis-Schiff base iron complex and a preparation method and application thereof. Five 5-halogenated salicylaldehyde diamine bis-Schiff base ligands are synthesized by condensation polymerization of 1,3-propylenediamine or its derivatives with 5-halogenated salicylaldehyde, and these ligands are reacted with Fe(II) to obtain Fe(III) complexes 1-5, and the complexes 1-5 have good anti-cancer activity and selectivity.
Need to check novelty before this filing date? Find Prior Art